Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free BON Stock Alerts

Bon Natural Life (BON) Competitors

Bon Natural Life logo
$1.28 +0.03 (+2.11%)
Closing price 03:52 PM Eastern
Extended Trading
$1.27 -0.01 (-0.49%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BON vs. ATRA, ATNM, ALGS, HOWL, and ATHE

Should you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Atara Biotherapeutics (ATRA), Actinium Pharmaceuticals (ATNM), Aligos Therapeutics (ALGS), Werewolf Therapeutics (HOWL), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry.

How does Bon Natural Life compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Atara Biotherapeutics has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500.

Atara Biotherapeutics has a net margin of 27.07% compared to Bon Natural Life's net margin of 0.00%. Bon Natural Life's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atara Biotherapeutics27.07% -79.12% 87.55%
Bon Natural Life N/A N/A N/A

Atara Biotherapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 26.05%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Atara Biotherapeutics is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atara Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Atara Biotherapeutics has higher revenue and earnings than Bon Natural Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara Biotherapeutics$120.77M0.34$32.69M$3.121.53
Bon Natural Life$18.67M0.56-$2MN/AN/A

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Atara Biotherapeutics had 21 more articles in the media than Bon Natural Life. MarketBeat recorded 21 mentions for Atara Biotherapeutics and 0 mentions for Bon Natural Life. Atara Biotherapeutics' average media sentiment score of 0.00 beat Bon Natural Life's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Atara Biotherapeutics Neutral
Bon Natural Life Neutral

Summary

Atara Biotherapeutics beats Bon Natural Life on 10 of the 13 factors compared between the two stocks.

How does Bon Natural Life compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Actinium Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500.

Bon Natural Life's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Actinium PharmaceuticalsN/A -100.85% -47.89%
Bon Natural Life N/A N/A N/A

Bon Natural Life has higher revenue and earnings than Actinium Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium Pharmaceuticals$90K439.25-$48.82M-$1.08N/A
Bon Natural Life$18.67M0.56-$2MN/AN/A

Actinium Pharmaceuticals currently has a consensus price target of $4.50, suggesting a potential upside of 257.14%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Actinium Pharmaceuticals is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score.

Company Overall Sentiment
Actinium Pharmaceuticals Neutral
Bon Natural Life Neutral

Summary

Actinium Pharmaceuticals beats Bon Natural Life on 6 of the 11 factors compared between the two stocks.

How does Bon Natural Life compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Aligos Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500.

Bon Natural Life has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,106.72%. Bon Natural Life's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-1,106.72% -28.16% -20.01%
Bon Natural Life N/A N/A N/A

Bon Natural Life has higher revenue and earnings than Aligos Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$2.19M17.98-$24.19M-$8.59N/A
Bon Natural Life$18.67M0.56-$2MN/AN/A

Aligos Therapeutics currently has a consensus price target of $41.50, suggesting a potential upside of 553.54%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 4.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Aligos Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Aligos Therapeutics and 0 mentions for Bon Natural Life. Aligos Therapeutics' average media sentiment score of 0.27 beat Bon Natural Life's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aligos Therapeutics Neutral
Bon Natural Life Neutral

Summary

Aligos Therapeutics beats Bon Natural Life on 9 of the 15 factors compared between the two stocks.

How does Bon Natural Life compare to Werewolf Therapeutics?

Bon Natural Life (NASDAQ:BON) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Bon Natural Life has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

In the previous week, Werewolf Therapeutics had 9 more articles in the media than Bon Natural Life. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 0 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.71 indicating that Bon Natural Life is being referred to more favorably in the media.

Company Overall Sentiment
Bon Natural Life Neutral
Werewolf Therapeutics Negative

Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 459.95%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bon Natural Life's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bon Natural LifeN/A N/A N/A
Werewolf Therapeutics N/A -158.82%-69.75%

Bon Natural Life has higher revenue and earnings than Werewolf Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bon Natural Life$18.67M0.56-$2MN/AN/A
Werewolf Therapeutics$1.88M17.31-$60.82M-$1.36N/A

Summary

Werewolf Therapeutics beats Bon Natural Life on 7 of the 13 factors compared between the two stocks.

How does Bon Natural Life compare to Alterity Therapeutics?

Bon Natural Life (NASDAQ:BON) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

In the previous week, Alterity Therapeutics had 2 more articles in the media than Bon Natural Life. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.43 indicating that Bon Natural Life is being referred to more favorably in the media.

Company Overall Sentiment
Bon Natural Life Neutral
Alterity Therapeutics Neutral

Bon Natural Life has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bon Natural Life has higher revenue and earnings than Alterity Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bon Natural Life$18.67M0.56-$2MN/AN/A
Alterity TherapeuticsN/AN/A-$7.87MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Company Net Margins Return on Equity Return on Assets
Bon Natural LifeN/A N/A N/A
Alterity Therapeutics N/A N/A N/A

Summary

Alterity Therapeutics beats Bon Natural Life on 6 of the 9 factors compared between the two stocks.

Get Bon Natural Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BON vs. The Competition

Export
MetricBon Natural LifeCONSM PD IndustryDiscretionary SectorNASDAQ Exchange
Market Cap$10.38M$1.46B$7.12B$11.87B
Dividend YieldN/A3.97%2.87%5.21%
P/E RatioN/A9.9816.9528.48
Price / Sales0.565.043.7460.89
Price / CashN/A16.6913.0036.52
Price / Book0.181.433.566.67
Net Income-$2M$66.99M$267.38M$332.64M
7 Day Performance-2.48%-0.53%-0.87%2.01%
1 Month Performance-0.29%5.15%5.79%9.19%
1 Year PerformanceN/A15.23%10.58%39.59%

Bon Natural Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BON
Bon Natural Life
0.3123 of 5 stars		$1.28
+2.1%		N/AN/A$10.38M$18.67MN/A100
ATRA
Atara Biotherapeutics
2.5861 of 5 stars		$5.01
flat		$6.00
+19.8%		N/A$40.98M$120.77M1.61330
ATNM
Actinium Pharmaceuticals
2.1544 of 5 stars		$1.28
flat		$4.50
+251.6%		N/A$40.16M$90KN/A30
ALGS
Aligos Therapeutics
3.6714 of 5 stars		$6.40
flat		$41.50
+548.4%		N/A$39.62M$2.19MN/A90
HOWL
Werewolf Therapeutics
2.6204 of 5 stars		$0.81
flat		$3.75
+361.3%		N/A$39.51M$1.88MN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BON) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel